ACBI1

Cat. No.:	HY-128359
CAS No.:	2375564-55-7
Molecular Formula:	$C_{49}H_{58}FN_9O_7S$
Molecular Weight:	936.1
Target:	PROTAC; Epigenetic Reader Domain; Apoptosis
Pathway:	PROTAC; Epigenetics; Apoptosis
Storage:	-20°C, protect from light, stored under argon * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light, stored under argon)



SOLVENT & SOLUBILITY

In Vitro

DMSO : ≥ 100 mg/mL (106.83 mM)

* "≥" means soluble, but saturation unknown.

Preparing Stock Solutions

Solvent / Mass / Concentration	1 mg	5 mg	10 mg
1 mM	1.0683 mL	5.3413 mL	10.6826 mL
5 mM	0.2137 mL	1.0683 mL	2.1365 mL
10 mM	0.1068 mL	0.5341 mL	1.0683 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

1. Add each solvent one by one: **10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline**
   Solubility: ≥ 2.5 mg/mL (2.67 mM); Clear solution
2. Add each solvent one by one: **10% DMSO >> 90% corn oil**
   Solubility: ≥ 2.5 mg/mL (2.67 mM); Clear solution

BIOLOGICAL ACTIVITY

Description

ACBI1 is a potent **PROTAC** degrader of BAF ATPase subunits **SMARCA2** and **SMARCA4**, also degrades the polybromo-associated BAF (PBAF) complex member **PBRM1**, with **DC_{50}**s of 6 nM, 11 nM and 32 nM for SMARCA2, SMARCA4 and PBRM1 in MV-4-11 cells, respectively. ACBI1 is composed of a bromodomain ligand, a linker, and the E3 ubiquitin ligase VHL. ACBI1 can induce anti-proliferative effects and apoptosis[1].

IC_{50} & Target

DC50: 6 nM (SMARCA2), 11 nM (SMARCA4), 32 nM (PBRM1)[1]

REFERENCES

[1]. Farnaby W, et al. BAF complex vulnerabilities in cancer demonstrated via structure-based PROTAC design. Nat Chem Biol. 2019 Jul;15(7):672-680.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA